Evaluating the Pharmacokinetics and Safety of Miricorilant

Conditions

• Nonalcoholic Steatohepatitis (NASH)
• Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
• Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
• Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

• DRUG: Miricorilant

Sponsor

Corcept Therapeutics